A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

Chemoimmunotherapy regimens have been the standard first-line therapy for patients with chronic lymphocytic leukemia (CLL). For young, fit patients the standard of care is combination of fludarabine, cyclophosphamide, and rituximab (FCR). Based on the preclinical work demonstrating that bendamustine...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400650/
https://www.ncbi.nlm.nih.gov/pubmed/27655665
http://dx.doi.org/10.18632/oncotarget.12054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400650/
https://www.ncbi.nlm.nih.gov/pubmed/27655665
http://dx.doi.org/10.18632/oncotarget.12054

Ejemplares similares